Madrigal Pharmaceuticals stock holds above 530 dollars after recent ownership change

Published on 09/20/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Madrigal Pharmaceuticals stock opened at 531.52 dollars on September 18, 2026, according to MarketBeat data. Institutional buying by Bank of America Corp DE adds a fresh ownership signal for investors.

MDGL, US5563691094, Illustration mit AI erstellt.

Madrigal Pharmaceuticals, Inc. stock (ISIN US5563691094) opened at USD 531.52 on September 18, 2026, giving investors a clear picture of the company’s current valuation after fresh institutional buying activity reported in mid-September 2026.

Institutional buying supports the share price

According to MarketBeat on September 20, 2026, Bank of America Corp DE disclosed a position of 134,036 shares in Madrigal Pharmaceuticals, Inc., signaling continued institutional interest in the biotech company.

In the same filing summary, MarketBeat reported that Madrigal Pharmaceuticals stock opened at USD 531.52 on September 18, 2026, with the figure serving as a recent reference level for investors assessing the impact of institutional flows.

Recent trading level and valuation context

At an opening price of USD 531.52 as of September 18, 2026, Madrigal Pharmaceuticals stock trades at a high absolute level compared with many mid-cap biotech peers, reflecting expectations around its liver disease portfolio and the lead drug resmetirom.

The institutional stake of 134,036 shares reported by Bank of America Corp DE on September 20, 2026, represents a sizable single-holder position and can be used by investors as a signal that large financial institutions are willing to commit capital at current price levels.

Stock price checkpoint

Based on the MarketBeat snapshot for September 18, 2026, Madrigal Pharmaceuticals stock can be referenced at an opening level of USD 531.52 on Nasdaq, giving investors a recent price checkpoint to compare against prior trading ranges and future moves.